Showing 1–25 of 28 documents
Sorted by hybrid relevance (keyword + semantic via RRF)
Qi Nie, Yuan Liu, Fan Xiao, Yong Zhou, Tingting Fu, et al.
…extensively drug-resistant tuberculosis (pre-XDR-TB) during pregnancy poses a formidable clinical challenge, particularly when complicated by tuberculous meningoencephalomyelitis (TBMEM), While the WHO operational handbook provides a general framework for drug-resistant TB, robus…
Joelma Patrícia Gonçalves Mateia Pio, Marcelo Nóbrega Litvoc, Hermes Ryoiti Higashino, Vivalda Ndahafa Hinamito, Igor C. Borges
… antimicrobial selection due to its resistance profile, and pregnancy makes this situation even more challenging due to additional restrictions related to the risk of fetal toxicity. Female patient, 31 years old, with a past history of pleural TB in 2018, diagnosed with pulmonary…
Ameya D. Bendre, Pooja Singh, Swati Jaiswal
…s review highlights immune-neuroendocrine reactivity during pregnancy, a state that alters maternal immunity and increases vulnerability to TB (https://doi.org/10.3389/fmed.2025.1503402). Pregnancy introduces unique immunological challenges for TB management. Hormonal changes dur…
Wang L, Zhang X, Wang W, Huang F
We reported a late-pregnancy woman with pre-XDR PTB who had not received regular anti-tuberculosis treatment prior to delivery. Despite this, she successfully delivered a premature baby who exhibited normal growth and development, and subsequently completed her anti-tuberculosis …
Shuang Wei, M.D.
…men of childbearing age, not pregnant, willing to undergo a pregnancy test with a negative result, and willing to use highly effective contraceptive measures from signing the informed consent until 3 months after the end of the study treatment. For men of childbearing age, using…
David S.C. Hui, Chi Chiu Leung
… in the ongoing TB epidemic.50 The safety of rifapentine in pregnancy remains to be established even though no excess risks of foetal loss or congenital anomalies were observed among pregnant women inadvertently exposed to either isoniazid or isoniazid plus rifapentine in two cli…
Charles Horsburgh, MD, Payam Nahid, MD
Multidrug-resistant tuberculosis (MDR-TB) is tuberculosis (TB) that is resistant to at least isoniazid and rifampicin, the two most important anti-TB drugs. It occurs in 3.6% of newly diagnosed TB patients in the world and 17% of patients who have been previously treated. In 2017…
Anne Margarita Dyrhol-Riise, PhD
Tuberculosis (TB) is a global challenge and for the increasing epidemic of multi-drug resistant (MDR)-TB there is restricted treatment options. This calls for research of new immune-modulating treatment strategies that can strengthen the patients immune system to better fight the…
Clifton E Barry, Ph.D.
This study, conducted jointly by researchers at the National Masan TB Hospital, Asan and Samsung Medical Centers in Seoul, Republic of Korea, and the Yonsei University and the NIH in the United States, will examine why some patients with tuberculosis (TB) develop disease that is …
Clifton Barry, Ph.D.
This study, conducted in Masan and Seoul, South Korea, investigated the effectiveness of linezolid (LZD) in treating patients with extensively drug resistant tuberculosis (XDR TB). Because regular medicines do not work well against XDR TB, many more people die from it than from r…
Keertan Dheda, MBChB
This study aims to evaluate the impact of a new injection-free six-to-nine month treatment regimen of linezolid, bedaquiline, levofloxacin, pyrazinamide (PZA) and ethionamide/high dose isoniazid (INH) compared to the conventional empiric injection-based regimen. The secondary aim…
Wafaie W Fawzi, MBBS, MPH, MS, DrPH
India has the highest incidence of and mortality from multi-drug resistant tuberculosis (MDR-TB) globally. Vitamin D status may be an important determinant of MDR-TB infection and treatment outcomes; however, observational evidence is insufficient to support its use as an adjunct…
Jan-Willem C Alffenaar, PharmD PhD
Rationale: Treatment of multidrug or extensively drug resistant tuberculosis (MDR/XDR-TB) is a real challenge as failure in response to treatment and serious side-effects are frequently encountered. New, more effective drugs with less side effects are therefore urgently needed t…
University Medical Center Groningen
Rationale: Treatment of multidrug or extensively drug resistant tuberculosis (MDR/XDR-TB) is a real challenge as failure in response to treatment and serious side-effects are frequently encountered. New, more effective drugs with less side effects are therefore urgently needed t…
Pedersen OS, Holmgaard FB, Mikkelsen MKD, Lange C, Sotgiu G, et al.
Introduction Historically, extensively drug-resistant tuberculosis has been notoriously difficult to treat with devasting outcomes. As we are coming to the end of an era where the 2006 extensively drug-resistant tuberculosis definitions and old treatment regimens are being replac…
Jan-Willem C Alffenaar, PhD, PharmD
Future patients might benefit from a combination of linezolid (LIN) and clarithromycin (CLA) in the treatment of Multidrug-resistant and Extensively Drug-resistant Tuberculosis (MDR/XDR-TB) due to possible synergistic activity as shown in in vitro experiments in different Mycobac…
University Medical Center Groningen
Rationale: Multidrug-resistant tuberculosis (MDR-TB) is defined as tuberculosis resistant to isoniazid and rifampicin. The incidence of MDR-TB worldwide is 3.9% for new cases and 21% for previously treated cases. However, the incidence of previously treated cases can rise to abov…
Naomi E. Aronson, MD, Merlin L. Robb, MD
The purpose of this research is to find out if a single dose of pre-travel vaccination with BCG can lessen tuberculosis (TB) infection by producing an immune response when given to adults traveling to countries with a high or moderate burden of TB. BCG will be compared with a pla…
Francesca Conradie
To evaluate the efficacy, safety and tolerability of various doses and durations of linezolid plus bedaquiline and pretomanid after 26 weeks of treatment in participants with either pulmonary XDR-TB, pre-XDR-TB, or treatment intolerant or non-responsive MDR-TB. A phase 3, multi-…
Morounfolu Olugbosi, MD, Francesca Conradie, MD
The purpose of this study is to evaluate the efficacy, safety, tolerability and pharmacokinetics of bedaquiline plus PA-824 plus linezolid after 6 months of treatment (option for 9 months for participants who remain culture positive at month 4) in participants with either pulmona…
Deshpande D, Srivastava S, Bendet P, Martin KR, Cirrincione KN, et al.
The modern chemotherapy era started with Fleming's discovery of benzylpenicillin. He demonstrated that benzylpenicillin did not kill Mycobacterium tuberculosis In this study, we found that >64 mg/liter of static benzylpenicillin concentrations killed 1.16 to 1.43 log 10 CFU/ml be…
Dr Mahmoud R Elkazzaz, M.Sc of Biochemistry, Amr K Ahmed
Utilizing the Crosstalk Among Chicoric Acid, 13-Cis Retinoic Acid(Aerosolized), Minocycline and Vitamin D as a Potent Quadrate Therapy for treating patients with Multidrug-resistant TB and patient with both Multidrug-resistant TB and COVID-19 . A double-edged sword Clinical Study…
sha wei
Tuberculosis is the current leading cause of death due to an identifiable infectious agent worldwide. The current standard regimen for tuberculosis requires a patient to take drug combination (isoniazid, rifampicin, ethambutol, and pyrazinamide) for six to eight month periods. Th…
Padmapriyadarsini Chandrasekharan
Existing problem with DR TB management: Injectable regimens for longer duration with toxicity Poor adherence, treatment failures, continued transmission Need of the study: Oral regimens of shorter duration Improved treatment adherence Implementation of community-based models o…
Eric R Houpt, MD
This is protocol is generated in response to the exploratory R21 from the National Institutes of Health/National Institute of Allergy and Infectious Diseases (NIH/NIAID) for US-Russia collaborative research in HIV/tuberculosis (TB). Given the exploratory focus of the protocol and…